A Phase Ib Study of Linperlisib Monotherapy in Patients with Relapsed or Refractory B-Cell Malignancies

被引：1
|
作者：
Liu, Wei [1 ]
Huang, Yunhong [2 ]
Yang, Haiyan [3 ]
Li, Zhiming [4 ]
Cai, Zhen [5 ]
Wang, Zhen [6 ]
Liu, Lihong [7 ]
Guo, Ye [8 ]
Liu, Ligen [9 ]
Huang, Rui [10 ]
Ye, Xu [11 ]
Qiu, Lugui [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis, Inst Hematol & Blood Dis Hosp,Haihe Lab Cell Ecos, Tianjin, Peoples R China
[2] Guizhou Med Univ, Affiliated Canc Hosp, Guiyang, Peoples R China
[3] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[4] State Key Lab Oncol South China, Guangzhou, Peoples R China
[5] Zhejiang Univ, Sch Med, Bone Marrow Transplantat Ctr, Affiliated Hosp 1, Hangzhou, Peoples R China
[6] Linyi Canc Hosp, Linyi, Peoples R China
[7] Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China
[8] Shanghai East Hosp, Shanghai, Peoples R China
[9] Shanghai Jiao Tong Univ, Sch Med, Tongren Hosp, Shanghai, Peoples R China
[10] Southern Med Univ, Zhujiang Hosp, Guangzhou, Peoples R China
[11] Guangzhou Med Univ, Dept Hematol, Affiliated Hosp 2, Guangzhou, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-177550
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] CAR22/19 Cocktail Therapy for Patients with Refractory/Relapsed B-Cell Malignancies
    Huang, Liang
    Wang, Na
    Cao, Yang
    Li, Chunrui
    Xiao, Yi
    Xiao, Min
    Zhou, Xiaoxi
    Wang, Gaoxiang
    Hong, Zhenya
    Zhen, Miao
    Meng, Weixu
    Zhang, Bin
    Zhang, Yicheng
    Marcucci, Guido
    Zhang, Tongcun
    Zhou, Jianfeng
    BLOOD, 2018, 132
  • [42] Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study
    Awan, Farrukh T.
    Thirman, Michael J.
    Patel-Donnelly, Dipti
    Assouline, Sarit
    Rao, Arati, V
    Ye, Wei
    Hill, Brian
    Sharman, Jeff P.
    LEUKEMIA & LYMPHOMA, 2019, 60 (08) : 1972 - 1977
  • [43] Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma
    Graf, Solomon A.
    Cassaday, Ryan D.
    Morris, Karolyn
    Voutsinas, Jenna M.
    Wu, Qian Vicky
    Behnia, Sanaz
    Lynch, Ryan C.
    Krakow, Elizabeth
    Rasmussen, Heather
    Chauncey, Thomas R.
    Kanan, Sandra
    Soma, Lorinda
    Smith, Stephen D.
    Gopal, Ajay K.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (03): : 176 - 181
  • [44] Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies
    Munakata, Wataru
    Ando, Kiyoshi
    Yokoyama, Masahiro
    Fukuhara, Noriko
    Yamamoto, Kazuhito
    Fukuhara, Suguru
    Ohmachi, Ken
    Mishima, Yuko
    Ichikawa, Satoshi
    Ogiya, Daisuke
    Aoi, Arata
    Hatsumichi, Masahiro
    Tobinai, Kensei
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117 (04) : 553 - 562
  • [45] Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies
    Wataru Munakata
    Kiyoshi Ando
    Masahiro Yokoyama
    Noriko Fukuhara
    Kazuhito Yamamoto
    Suguru Fukuhara
    Ken Ohmachi
    Yuko Mishima
    Satoshi Ichikawa
    Daisuke Ogiya
    Arata Aoi
    Masahiro Hatsumichi
    Kensei Tobinai
    International Journal of Hematology, 2023, 117 : 553 - 562
  • [46] Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy
    Landsburg, Daniel J.
    Hughes, Mitchell E.
    Koike, Alexa
    Bond, David
    Maddocks, Kami J.
    Guo, Ling
    Winter, Allison M.
    Hill, Brian T.
    Ondrejka, Sarah L.
    Hsi, Eric D.
    Nasta, Sunita D.
    Svoboda, Jakub
    Schuster, Stephen J.
    Bogusz, Agata M.
    BLOOD ADVANCES, 2019, 3 (02) : 132 - 135
  • [47] A Phase 1 Study Evaluating PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Select Relapsed/Refractory B-Cell Malignancies
    Cheson, Bruce D.
    Shouse, Geoffrey P.
    Assouline, Sarit
    Lewis, Katharine L.
    Hawkes, Eliza A.
    Munir, Talha
    Davies, Andrew S.
    Langerbeins, Petra
    Tam, Constantine S.
    Gregory, Gareth P.
    Choi, Michael Y.
    Sun, William
    Atwal, Siminder K.
    Hong, Wan-Jen
    Sarkozy, Clementine
    BLOOD, 2023, 142
  • [48] Phase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma
    Nastoupil, Loretta J.
    Kuruvilla, John
    Chavez, Julio C.
    Bijou, Fontanet
    Witzig, Thomas E.
    Santoro, Armando
    Flinn, Ian W.
    Boccomini, Carola
    Kenkre, Vaishalee P.
    Corradini, Paolo
    Isufi, Iris
    Andorsky, David J.
    Klein, Leonard M.
    Greenwald, Daniel R.
    Sangha, Randeep
    Shen, Frank
    Hagner, Patrick
    Li, Yan
    Dobmeyer, Juergen
    Gong, Nian
    Uttamsingh, Shailaja
    Pourdehnad, Michael
    Ribrag, Vincent
    EJHAEM, 2022, 3 (02): : 394 - 405
  • [49] Ibrutinib in Association with R-DHAP/Ox for Patients with Relapsed/Refractory B-Cell Lymphoma: Preliminary Results of the Biblos Phase Ib Lysa Study
    Bonnet, Christophe
    Lamy, Thierry
    Fruchart, Christophe
    Le Gouill, Steven
    Gunzer, Katharina
    Gastinne, Thomas
    Jardin, Fabrice
    Karlin, Lionel
    Houot, Roch
    Dupuis, Jehan
    Tilly, Herve
    Salles, Gilles A.
    BLOOD, 2016, 128 (22)
  • [50] Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma
    Kato, Koji
    Makita, Shinichi
    Goto, Hideki
    Kanda, Junya
    Fujii, Nobuharu
    Shimada, Kazuyuki
    Akashi, Koichi
    Izutsu, Koji
    Teshima, Takanori
    Fukuda, Natsuko
    Sumitani, Tokuhito
    Sumi, Hiroyuki
    Shimizu, Shinji
    Kakurai, Yasuyuki
    Yoshikawa, Kenji
    Tobinai, Kensei
    Usui, Noriko
    Hatake, Kiyohiko
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (01) : 213 - 223
12345